Zhou Hongli, Zeng Xiaojing, Sun Dongchen, Chen Zhe, Chen Weixin, Fan Liwei, Limpanont Yanin, Dekumyoy Paron, Maleewong Wanchai, Lv Zhiyue
Joint Program of Pathobiology, Fifth Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
NHC Key Laboratory of Control of Tropical Diseases, Hainan Medical University, Haikou, China.
Front Microbiol. 2021 Jan 5;11:606605. doi: 10.3389/fmicb.2020.606605. eCollection 2020.
Inflammatory bowel disease (IBD)-related inflammation is closely associated with the initiation and progression of colorectal cancer. IBD is generally treated with 5-aminosalicylic acid and immune-modulating medication, but side effects and limitations of these therapies are emerging. Thus, the development of novel preventative or therapeutic approaches is imperative. Here, we constructed a dextran sodium sulphate (DSS)-induced IBD mouse model that was infected with monosexual cercariae (mSjci) at day 1 or administered dexamethasone (DXM) from days 3 to 5 as a positive control. The protective effect of mSjci on IBD mice was evaluated through their assessments of their clinical signs, histopathological lesions and intestinal permeability. To uncover the underlying mechanism, the Th1/Th2 balance and Treg cell population were also examined. Additionally, the alterations in the gut microbiota were assessed to investigate the interaction between the mSjci-modulated immune response and pathogenic microbiome. Mice treated with DSS and mSjci showed fewer IBD clinical signs and less impaired intestinal permeability than DSS-treated mice. Mechanistically, mSjci modulated the Th1/Th2 balance by repressing IFN-γ production, promoting IL-10 expression and enhancing the Treg subset population. Moreover, mSjci notably reshaped the structure, diversity and richness of the gut microbiota community and subsequently exerted immune-modulating effects. Our findings provide evidence showing that mSjci might serve as a novel and effective protective strategy and that the gut microbiota might be a new therapeutic target in IBD.
炎症性肠病(IBD)相关炎症与结直肠癌的发生和发展密切相关。IBD通常采用5-氨基水杨酸和免疫调节药物治疗,但这些疗法的副作用和局限性日益显现。因此,开发新的预防或治疗方法势在必行。在此,我们构建了葡聚糖硫酸钠(DSS)诱导的IBD小鼠模型,在第1天用单性尾蚴(mSjci)感染该模型,或从第3天至第5天给予地塞米松(DXM)作为阳性对照。通过评估mSjci对IBD小鼠的临床症状、组织病理学损伤和肠道通透性,来评价其对IBD小鼠的保护作用。为揭示潜在机制,还检测了Th1/Th2平衡和调节性T细胞(Treg)群体。此外,评估肠道微生物群的变化,以研究mSjci调节的免疫反应与致病微生物群之间的相互作用。与仅用DSS处理的小鼠相比,用DSS和mSjci处理的小鼠IBD临床症状更少,肠道通透性受损程度更低。从机制上讲,mSjci通过抑制IFN-γ产生、促进IL-10表达和增加Treg亚群数量来调节Th1/Th2平衡。此外,mSjci显著重塑了肠道微生物群的结构、多样性和丰富度,随后发挥免疫调节作用。我们的研究结果提供了证据,表明mSjci可能是一种新型有效的保护策略,肠道微生物群可能是IBD的一个新治疗靶点。